Αποτελέσματα Αναζήτησης
Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model.
7 Αυγ 2024 · Most patients with glioblastoma are managed with a combined-modality approach, incorporating adjuvant postoperative radiation therapy and adjuvant chemotherapy following initial surgery. Even with maximal therapy, glioblastoma has a high rate of recurrence and poor overall survival, ranging from 1.5 to 2 years.
15 Μαρ 2023 · 6 Citations. Explore all metrics. Abstract. Backg round. Glioblastoma is an aggressive tumor that has a dismal prognosis even with multimodal treatment. However, some patients survive longer than expected.
15 Ιουλ 2020 · Translation of survival benefits observed in glioblastoma clinical trials to populations and to longer-term survival remains uncertain. We aimed to assess if ≥ 2-year survival has changed...
Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours.
11 Νοε 2021 · Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in glioblastoma, a highly aggressive brain tumor in adults with dismal prognosis. Yet,...
17 Φεβ 2022 · Gross total resection was achieved in 113 patients (48.92%). In the molGBM group, 22 patients (33.85%) were 65 years or older and 22 patients (33.85%) were female. Most patients were of non-hispanic white race (n = 61, 93.85%). 15 patients (23.08%) had a KPS of 70 or below.
